Biofidelity

Biofidelity develops molecular technologies, including the Aspyre and Enspyre platforms, designed for genomic biomarker detection throughout the cancer patient journey. The company provides reagents and clinical testing services to healthcare providers, laboratories, and biopharma partners to facilitate treatment selection and minimal residual disease monitoring. These solutions aim to simplify the analysis of genomic data to match patients with targeted therapies.